Honokiol for Early-Stage Lung Cancer Before Surgery

This study is testing a dietary supplement called honokiol in people with early-stage non-small cell lung cancer (NSCLC) before they have surgery. The main goal is to find the highest dose of honokiol that can be given safely (Maximum Tolerated Dose). You might be able to join if you are 18 or older, have early-stage NSCLC (stage I, less than 4 cm) that is planned for surgery, and are able to give written consent. About 15 patients will take honokiol for two weeks before their surgery. The study status is currently unclear.

Study design
This is a Phase I study, meaning it focuses on safety. It plans to enroll about 15 participants.
What's involved
Participants will take honokiol orally for 2 weeks prior to surgery. The dose may increase based on how well it's tolerated.
Compensation
Not stated in the trial record.
Follow-up
The Maximum Tolerated Dose will be assessed up to 21 days after the last patient starts treatment, and up to 2 years after the first patient enrolls.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06566443

Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Recruiting
PHASE1Ages 18+InterventionalPrevention
The Methodist Hospital Research Institute
~15 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:Honokiol

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Tolerated Dose of Honokiol therapy
Measured over From treatment initiation of each patient, assessed up to 21 days after treatment initiation of final patient, up to 2 years after first enrollment.
Carcinoma, Non-Small-Cell Lung
1 sites across 1 states
Texas1
  • Jun Zhang, MD · PRINCIPAL_INVESTIGATOR · Houston Methodist Neal Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

  • Maximum Tolerated Dose of Honokiol therapyFrom treatment initiation of each patient, assessed up to 21 days after treatment initiation of final patient, up to 2 years after first enrollment.

    To determine the maximum tolerated dose (MTD) of honokiol therapy in patients with stage I NSCLC, less than 4 cm, who will undergo surgical resection. Review the safety data to determine the dose level at which the maximum tolerable level of toxicity is observed and select as the MTD the dose for which the isotonic estimate of the DLT rate is closest to the target DLT rate.